Partha Anbil

Partha Anbil and Partha Khot examine what makes patient support programs succeed, industry adoption trends, key criticisms, and the strategic path forward.

In the first half of this analysis, Partha Anbil and Partha Khot examine how patient support programs cut discontinuation and improve patient outcomes, reshaping hub services into an industry standard.

AI-powered automation is transforming pharmacovigilance, cutting AE case intake time amid record FAERS volumes and new FDA/EMA regulatory guidance.

Pharma supply chains are embracing AI, digital twins, IoT, and DSCSA-driven traceability to improve resilience, visibility, and profitability amid rising global disruptions.

This guide outlines a proven framework, spanning process, people, and platform, to help healthcare innovators scale AI with compliance, collaboration, and clinical impact in mind.

Life sciences organizations have an opportunity to move beyond patient-centered care and embrace a model that values lived experience, fosters collaboration, and positions patients as active contributors to research, treatment, and innovation.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Cloud-based IT technologies are a natural fit for patient-support hubs